• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by OraSure Technologies Inc.

    2/8/22 5:30:07 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care
    Get the next $OSUR alert in real time by email
    SC 13G 1 osur13ginitial1221.txt ORASURE TECHNOLOGIES, INC. - 12/31/2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No._ _) ORASURE TECHNOLOGIES, INC. ------------------------------------------------------------------------------- (Name of Issuer) Common Stock ------------------------------------------------------------------------------- (Title of Class of Securities) 68554V108 ------------------------------ (CUSIP Number) 12/31/2021 ------------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP NO. 68554V108 --------- ------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). EARNEST Partners, LLC ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [ ] (b) [ ] ------------------------------------------------------------------------------- 3 SEC USE ONLY ------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ------------------------------------------------------------------------------- 5 SOLE VOTING POWER 4,281,630 NUMBER OF ----------------------------------------------------------------- SHARES BENEFICIALLY 6 SHARED VOTING POWER 0 OWNED BY ----------------------------------------------------------------- EACH REPORTING 7 SOLE DISPOSITIVE POWER 4,871,379 PERSON WITH ----------------------------------------------------------------- 8 SHARED DISPOSITIVE POWER 0 ------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,871,379 ------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)[ ] ------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.8% ------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) ------------------------------------------------------------------------------- IA ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- Item 1 (a) Name of Issuer ORASURE TECHNOLOGIES, INC. (b) Address of Issuer's Principal Executive Offices 220 East First Street, Bethlehem, Pennsylvania, 18015 Item 2 (a) Name of Person Filing EARNEST Partners, LLC (b) Address of Principal Business Office or, if none, Residence 1180 Peachtree Street NE, Suite 2300, Atlanta, Georgia 30309 (c) Citizenship Delaware (d) Title of Class of Securities Common Stock (e) CUSIP Number 68554V108 Item 3. If this statement is filed pursuant to 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (b) [ ] Bank as defined in section 3(a)(6) of the Act (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (e) [X] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J). Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 4,871,379 (b) Percent of class: 6.8% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 4,281,630 (ii) Shared power to vote or to direct the vote 0 (iii) Sole power to dispose or to direct the disposition of 4,871,379 (iv) Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ] Item 6. Ownership of More than Five Percent on Behalf of Another Person. EARNEST Partners, LLC is filing as an investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). No client interest relates to more than five percent of the class. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not Applicable Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of a Group Not Applicable Item 10. Certification (a) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(b): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. (b) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(c): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2022 ---------------------------------- Date /s/ James M. Wilson ---------------------------------- Signature James M. Wilson Chief Compliance Officer ---------------------------------- Name/Title Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001) ACN/Form 13G (C) 2006: Advisor Consultant Network, Inc.
    Get the next $OSUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSUR

    DatePrice TargetRatingAnalyst
    1/3/2023$5.00In-line
    Evercore ISI
    2/24/2022$15.00 → $12.00Buy
    Citigroup
    9/22/2021Outperform → Market Perform
    Raymond James
    8/4/2021$11.00 → $12.50Outperform
    Raymond James
    6/28/2021$12.00 → $11.00Outperform
    Raymond James
    More analyst ratings

    $OSUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on OraSure with a new price target

    Evercore ISI resumed coverage of OraSure with a rating of In-line and set a new price target of $5.00

    1/3/23 8:07:55 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Citigroup reiterated coverage on OraSure Technologies with a new price target

    Citigroup reiterated coverage of OraSure Technologies with a rating of Buy and set a new price target of $12.00 from $15.00 previously

    2/24/22 8:34:18 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies downgraded by Raymond James

    Raymond James downgraded OraSure Technologies from Outperform to Market Perform

    9/22/21 5:02:16 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    SEC Filings

    View All

    SEC Form DEFA14A filed by OraSure Technologies Inc.

    DEFA14A - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    3/17/26 5:29:43 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by OraSure Technologies Inc.

    10-K - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    3/9/26 4:29:14 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies Inc. filed SEC Form 8-K: Leadership Update

    8-K - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    3/5/26 4:15:16 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

    Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to Force an Ill-Timed Sale Process BETHLEHEM, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OraSure" and the "Company") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today issued the following statement in response to Altai Capital's March 17, 2026, letter: OraSure's Board and management team are steadfast in our commi

    3/17/26 4:52:45 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

    Calls on Company to Reach a Fair Settlement that Appoints Altai Nominees Rishi Bajaj and John Bertrand to the Board Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. ("OraSure" or the "Company") (NASDAQ:OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the "Board") outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317768148/en/ In the letter, Altai calls

    3/17/26 9:15:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Announces Fourth Quarter 2025 Financial Results

    BETHLEHEM, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2025. "Our Q4 results were consistent with our expectations, and revenue of $26.8 million was above the midpoint of our guidance range," said Carrie Eglinton Manner, President and CEO of OTI. "We supported our customers in navigating a challenging funding environment in 2025, and we are encouraged to see increasing signs of stability in key segments as we enter 2026." She continued, "We are confident that OTI is positioned to return to g

    2/25/26 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mcgrath Kenneth J bought $66,030 worth of shares (22,021 units at $3.00), increasing direct ownership by 4% to 557,262 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/16/26 8:01:53 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    President & CEO Eglinton Manner Carrie bought $66,033 worth of shares (22,022 units at $3.00), increasing direct ownership by 1% to 2,158,574 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/16/26 8:01:38 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Director Gagliano Nancy J bought $4,982 worth of shares (2,100 units at $2.37), increasing direct ownership by 1% to 160,254 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    12/2/25 4:16:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Anthony Michele Marie

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/19/26 4:05:45 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Mcgrath Kenneth J bought $66,030 worth of shares (22,021 units at $3.00), increasing direct ownership by 4% to 557,262 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/16/26 8:01:53 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    President & CEO Eglinton Manner Carrie bought $66,033 worth of shares (22,022 units at $3.00), increasing direct ownership by 1% to 2,158,574 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/16/26 8:01:38 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

    SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    11/12/24 4:46:06 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

    SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    11/4/24 1:18:55 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by OraSure Technologies Inc.

    SC 13G - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    10/4/24 1:30:36 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Leadership Updates

    Live Leadership Updates

    View All

    Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

    Calls on Company to Reach a Fair Settlement that Appoints Altai Nominees Rishi Bajaj and John Bertrand to the Board Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. ("OraSure" or the "Company") (NASDAQ:OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the "Board") outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317768148/en/ In the letter, Altai calls

    3/17/26 9:15:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies Appoints Steven K. Boyd to its Board of Directors

    Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective  OraSure Board Has Added Three New Independent Directors in the Past Three Years Mara Aspinall to Step Down from the Board; Jack Kenny Appointed as Chair of the Board BETHLEHEM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of Steven K. Boyd to its Board of Directors, as a Class II director, effective immediately. The addition of Mr. Boyd is part of OraSure's ongoing Board refr

    10/28/25 4:22:03 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Appoints Anne Messing as Chief Commercial Officer

    BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer. Ms. Messing brings more than 25 years of commercial leadership experience across the healthcare industry, including in life sciences, diagnostics, and clinical laboratory services, with a proven track record of driving growth, building high-performing sales teams, and transforming strategic vision into demonstrable results and sustainable success. In her role at OTI, she will be responsible for Sales, Marketing, Strategic Alliance

    8/4/25 7:05:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Financials

    Live finance-specific insights

    View All

    OraSure Announces Fourth Quarter 2025 Financial Results

    BETHLEHEM, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2025. "Our Q4 results were consistent with our expectations, and revenue of $26.8 million was above the midpoint of our guidance range," said Carrie Eglinton Manner, President and CEO of OTI. "We supported our customers in navigating a challenging funding environment in 2025, and we are encouraged to see increasing signs of stability in key segments as we enter 2026." She continued, "We are confident that OTI is positioned to return to g

    2/25/26 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th

    BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended. About OraSure Technologies, Inc. OraSure Technologies, Inc. ("OraSure"

    2/9/26 4:15:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Announces Third Quarter 2025 Financial Results

    BETHLEHEM, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2025. "In Q3 we delivered $27.1 million of revenue. While some of our customers continue to experience elevated levels of uncertainty related to funding for public health programs and research, we remain confident in our opportunities to return to growth in 2026, driven by diversification in our customer base and contributions from planned launches of new products in both rapid diagnostics and sample management solutions," said Carrie

    11/5/25 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care